𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

✍ Scribed by Wayne J. Morgan; Steven M. Butler; Charles A. Johnson; Andrew A. Colin; Stacey C. FitzSimmons; David E. Geller; Michael W. Konstan; Michael J. Light; Harvey R. Rabin; Warren E. Regelmann; Daniel V. Schidlow; Dennis C. Stokes; Mary Ellen B. Wohl; Haley Kaplowitz; Matthew M. Wyatt

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
341 KB
Volume
28
Category
Article
ISSN
8755-6863

No coin nor oath required. For personal study only.

✦ Synopsis

for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

Summary. Cystic fibrosis (CF) is a complex illness characterized by chronic lung infection leading to deterioration in function and respiratory failure in over 85% of patients. An understanding of the risk factors for that progression and the interaction of these factors with current therapeutic strategies should materially improve the prevention of this progressive lung disease. The Epidemiologic Study of Cystic Fibrosis (ESCF) was therefore designed as a multicenter, longitudinal, observational study to prospectively collect detailed clinical, therapeutic, microbiologic, and lung function data from a large number of CF treatment sites in the U.S. and Canada. The ESCF also serves an important role as a phase-IV study of dornase alfa. To be eligible for enrollment, subjects must have the diagnosis of CF and receive the majority of their care at an ESCF site.

In this paper, the authors present the ESCF study design in detail. Further, enrollment data collected at 194 study sites in 18,411 subjects enrolled from December 1, 1993 to December 31, 1995 are presented in summary form. This comprehensive study is unique in the detail of clinical data collected regarding patient monitoring and therapeutic practices in CF care. Two companion articles present data regarding practice patterns in cystic fibrosis care, including data on resource utilization and prescribing practices.

πŸ“œ SIMILAR VOLUMES

Multicenter, open-label study of recombi
Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease
✍ H. Karsten Harms; Elias Matouk; Guy Tournier; Horst von der Hardt; Peter H. Well πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 58 KB πŸ‘ 1 views

Cystic fibrosis is characterized by the accumulation of thick viscous purulent secretions. Recombinant human deoxyribonuclease I (rhDNase) breaks down extracellular DNA, which contributes to the increased viscosity of sputum. A multinational, open-label study was conducted in 974 cystic fibrosis pat

Predicting the risk of cystic fibrosis w
Predicting the risk of cystic fibrosis with abnormal ultrasound signs of fetal bowel: Results of a French molecular collaborative study based on 641 prospective cases
✍ Muller, F. ;Simon-Bouy, B. ;Girodon, E. ;Monnier, N. ;Malinge, M.C. ;Serre, J.L. πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 75 KB

## Abstract Hyperechogenic fetal bowel is prenatally detected by ultrasound during the second trimester of pregnancy in 0.1–1.8% of fetuses. It has been described as a normal variant but has often been associated with severe diseases, notably cystic fibrosis (CF). The aim of our study was to determ

Missense mutation R1066C in the second t
Missense mutation R1066C in the second transmembrane domain of CFTR causes a severe cystic fibrosis phenotype: Study of 19 heterozygous and 2 homozygous patients
✍ T Casals; P Pacheco; C Barreto; J GimΓ©nez; MD Ramos; S Pereira; JA Pinheiro; N C πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 157 KB πŸ‘ 1 views

We report the clinical features of 21 unrelated cystic fibrosis (CF) patients from Portugal and Spain, who carry the mutation R1066C in the CFTR gene. The current age of the patients was higher in the R1066C/any mutation group (P < 0.01), as compared to the aF508/aF508 group. Poor values for lung ra

Aerosolized dornase alfa in cystic fibro
Aerosolized dornase alfa in cystic fibrosis: Is there a role in the management of patients with early obstructive lung disease?
✍ David E. Geller πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 1 views

Airway inflammation and infection are present in patients with mild lung disease in cystic fibrosis (CF), suggesting the need for early treatment. In a previously reported large multicenter trial, dornase alfa improved pulmonary function and decreased the need for hospitalization in patients with CF